Sign in
4/A

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-022649

PRESIDENT AND CEO sold 1,517 shares at $20.00 ($30,343)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Kintz Samuel · PRESIDENT AND CEO

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2025-08-20 Sale : show line 1 in the form 10b5-1 −1,517 $20.00 $30,343 927,892 I
Open-market sales · 1,517 sh · avg $20.00 · $30,343
Loading xslF345X05/form4a-08212025_100826.xml…